PFS. Data show PFS in patients with the FCGR2A 131 (A), FCGR2B 232 (B), or FCGR3A 158 (C) SNP genotype with FL treated with rituximab (R) or obinutuzumab (G) plus chemotherapy in the GALLIUM trial.